Cassava Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SAVA research report →
Companywww.cassavasciences.com
Cassava Sciences, Inc. , a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
- CEO
- Richard Jon Barry
- IPO
- 2000
- Employees
- 30
- HQ
- Austin, TX, US
Price Chart
Valuation
- Market Cap
- $94.44M
- P/E
- -0.78
- P/S
- 0.00
- P/B
- 0.89
- EV/EBITDA
- 0.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -99.85%
- ROIC
- -120.10%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-90,973,000 · -273.73%
- EPS
- $-1.88 · -254.72%
- Op Income
- $-95,390,000
- FCF YoY
- 71.95%
Performance & Tape
- 52W High
- $4.98
- 52W Low
- $1.15
- 50D MA
- $2.12
- 200D MA
- $2.51
- Beta
- -0.84
- Avg Volume
- 857.77K
Get TickerSpark's AI analysis on SAVA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 24, 25 | Anderson Robert Eugene Jr | buy | 8,600 |
| Nov 20, 25 | Barry Richard | buy | 150,000 |
| Nov 19, 25 | Barry Richard | buy | 73,385 |
| Oct 21, 25 | Bir Dawn Carter | other | 53,000 |
| Oct 21, 25 | Bir Dawn Carter | other | 0 |
| Sep 30, 25 | Cook Robert Christopher | buy | 13,725 |
| Sep 22, 25 | Barry Richard | buy | 7,172 |
| Sep 19, 25 | Barry Richard | buy | 46,908 |
| Sep 19, 25 | Barry Richard | buy | 400 |
| Sep 18, 25 | Barry Richard | buy | 185,233 |
Our SAVA Coverage
We haven't published any research on SAVA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SAVA Report →